- Home
- THAR vs CTHR Comparison
THAR vs CTHR Comparison
Compare THAR & CTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- CTHR
- Stock Information
- Founded
- THAR 2017
- CTHR 1995
- Country
- THAR United States
- CTHR United States
- Employees
- THAR N/A
- CTHR N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- CTHR Consumer Specialties
- Sector
- THAR Health Care
- CTHR Consumer Discretionary
- Exchange
- THAR Nasdaq
- CTHR Nasdaq
- Market Cap
- THAR 4.0M
- CTHR 4.1M
- IPO Year
- THAR 2022
- CTHR 1997
- Fundamental
- Price
- THAR $2.03
- CTHR $1.52
- Analyst Decision
- THAR Strong Buy
- CTHR
- Analyst Count
- THAR 1
- CTHR 0
- Target Price
- THAR $17.00
- CTHR N/A
- AVG Volume (30 Days)
- THAR 47.8K
- CTHR 24.6K
- Earning Date
- THAR 11-07-2024
- CTHR 02-11-2025
- Dividend Yield
- THAR N/A
- CTHR N/A
- EPS Growth
- THAR N/A
- CTHR N/A
- EPS
- THAR N/A
- CTHR N/A
- Revenue
- THAR N/A
- CTHR $23,684,860.00
- Revenue This Year
- THAR N/A
- CTHR $31.82
- Revenue Next Year
- THAR N/A
- CTHR N/A
- P/E Ratio
- THAR N/A
- CTHR N/A
- Revenue Growth
- THAR N/A
- CTHR N/A
- 52 Week Low
- THAR $1.84
- CTHR $1.16
- 52 Week High
- THAR $7.71
- CTHR $4.90
- Technical
- Relative Strength Index (RSI)
- THAR 45.25
- CTHR 55.10
- Support Level
- THAR $1.86
- CTHR $1.36
- Resistance Level
- THAR $2.06
- CTHR $1.56
- Average True Range (ATR)
- THAR 0.11
- CTHR 0.10
- MACD
- THAR -0.00
- CTHR 0.01
- Stochastic Oscillator
- THAR 38.64
- CTHR 80.04
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About CTHR Charles & Colvard Ltd
Charles & Colvard Ltd manufactures, markets, and distributes finished jewellery which also includes moissanite gemstone in the jewellery market. The company sells jewels through two operating segments namely Online Channels segment and Traditional segment. It generates maximum revenue from the Online Channels segment. Online Channels segment which consists of e-commerce outlets including charlesandcolvard.com, moissaniteoutlet.com, third-party online marketplaces, drop-ship retail, and other pure-play, exclusively e-commerce outlets.